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The chemotherapeutic potential of 1,10-phenanthroline (phen), and three of its transition metal complexes, namely
[Cu(phen)2(mal)] Æ 2H2O, [Mn(phen)2(mal)] Æ 2H2O and [Ag2(phen)3(mal)] Æ 2H2O (malH2 = malonic acid) was determined
using two human carcinoma cell lines (A-498 and Hep-G2). Phen and the three metal–phen complexes induced a concen-
tration-dependent cytotoxic effect, with metal complexes demonstrating the greatest cytotoxic response. In comparative
studies, IC50 values show cytotoxicity of between 3 and 18 times greater than that observed for the metal-based anti-cancer
agent, cisplatin. All of the phen-based complexes inhibited DNA synthesis which did not appear to be mediated through
intercalation. Also, the potential cancer chemotherapeutic application of these compounds was seen to be enhanced by
results obtained from Ames tests, which showed all of the test agents and their phase I metabolites were non-mutagenic.
Taken together, these results suggest that phen and the three metal–phen complexes may have a therapeutic role to play in
the successful treatment and management of cancer.
 2006 Elsevier Ireland Ltd. All rights reserved.
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Recently there have been a number of reports
highlighting the use of transition metal complexes
as anticancer agents [1]. Probably the best known
of these is cisplatin [cis-diamminedichloroplati-
num(II)]. It has been widely used in the treatmentreserved.
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with a 70–90% cure rate. When combined with other
drugs, it has successfully been used to treat brain,
ovarian, bladder and breast cancer [2]. The clinical
success of cisplatin is limited by its significant
side effects, such as nausea, vomiting and severe
nephrotoxicity [2]. The use of cisplatin and related
platinum complexes as anticancer agents has
stimulated a search for other active transition metal
complexes which are as effective, but with lesser side
effects.
1,10-Phenanthroline (Phen) (Fig. 1) and substi-
tuted derivatives, both in the metal-free state and
as ligands co-ordinated to transition metals, disturb
the functioning of a wide variety of biological sys-
tems [3]. Furthermore, when metal-free N,N’-chelat-
ing bases are found to be bioactive it is usually
assumed that sequestering of trace metals in situ
was involved, and that the resulting metal complexes
were the active species [4,5]. Previous work has
shown that the metal–phen complexes, [Cu(phen)2-
(mal)] Æ 2H2O, [Mn(phen)2(mal)] Æ 2H2O and [Ag2
(phen)3(mal)] Æ 2H2O (malH2 = malonic acid) inhib-
it the growth of Candida albicans by around 95% in
a concentration range of 1.25–5.0 lg/ml [6,7]. These
complexes induced extensive changes in the internal
structure of cells, including retraction of the cyto-
plasm, nuclear fragmentation and disruption of
the mitochondria [8]. From mechanistic studies it
was established that both metal-free phen and metal–
phen complexes affected mitochondrial function,
retarded synthesis of cytochromes b and c, and
uncoupled cellular respiration. Treatment of fungal
cells with Cu(II) and Ag(I) complexes resulted in a
reduced amount of ergosterol in the cell membrane
with consequent increases in permeability. Cells
exposed to metal-free phen and its Cu(II) and
Mn(II) complexes [but not the Ag(I) complex] dem-
onstrated an elevation in oxygen uptake. The general
conclusion was that these drugs damaged mitochon-
drial function and uncoupled respiration. Further-
more, the fact that they were not uniformly active
suggested that their bioactivity was dependent on
the central metal ion in the complex.N N
1,10-phenanthroline
(phen)
Fig. 1. Structure of 1,10-phenanthroline (phen).One of the most biologically active of the metal–
phen complexes is [Cu(phen)2]
2+. This agent has
been shown to promote hydroxyl radical formation
from molecular oxygen by redox-cycling and could
therefore be considered suitable for stimulation of
reactive oxygen species. Transition metal cations,
such as Cu(II) and Fe(II), can bind to negatively
charged DNA and have been shown to play an
important role in the local formation of OH radi-
cals [9,10]. One of the consequences of high copper
levels in the body is an increase in the rate of radical
formation leading to oxidative damage [11]. This
leads to a disruption of lipid bilayers due to oxida-
tion and cleavage of vulnerable unsaturated fatty
acid residues of phospholipids. Alterations in
protein function are also promoted through
oxidation of thiol and possibly amino groups. Gene
expression may also be altered due to oxidation of
guanosine and adenosine residues in nucleic acids,
or altered transcription factor/growth factor
activities [11]. Another possible consequence is
apoptosis. Tsang et al. [12] reported that incubation
of a human hepatic cell line (Hep-G2) with
[Cu(phen)2]
2+ resulted in internucleosomal DNA
fragmentation, a hallmark of apoptosis. Zhou
et al. [13] also reported G1-specific apoptosis in a
liver carcinoma cell line (Bel-7402), caused by
[Cu(phen)2]
2+. Additionally, this complex was also
shown to up-regulate DNA-binding activity of
p53, a pivotal molecule in the regulation of cell
progression, cell survival and apoptosis [14].
The primary aim of the current study was to
determine the cancer chemotherapeutic potential
of metal-free phen, [Cu(phen)2(mal)] Æ 2H2O,
[Mn(phen)2(mal)] Æ 2H2O and [Ag2(phen)3(mal)] Æ
2H2O, using two human-derived cancer model cell
lines of hepatic (Hep-G2) and renal (A-498) ori-
gin. In order to illustrate that the effect observed
was due to the complexes rather than the free
metal ions, the anti-tumour activities of the simple
Cu(II), Mn(II) and Ag(I) salts, Cu(ClO4)2,
Mn(ClO4)2 and AgClO4, were also determined.
In addition, the relative potency of these test
agents was determined by the inclusion of one
of the best known and most biologically active
metal-based anti-cancer agents, cisplatin. Further-
more, aspects of the molecular mechanisms
underlying the cytotoxic response were probed
by investigating the role of the complexes in
mediating DNA synthesis with intercalation.
This work represents the first thorough assess-
ment of the potential application of phen,
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and [Ag2 (phen)3(mal)] Æ 2H2O as novel therapeutic
agents for the treatment of cancer.
2. Materials and methods
2.1. Test compounds
1,10-Phenanthroline (phen), cisplatin, Cu(ClO4)2 Æ
6H2O, Mn(ClO4)2 Æ 6H2O, AgClO4, and dimethyl sulfox-
ide (DMSO) were purchased from Sigma-Aldrich, Ireland
Ltd., whilst [Cu(phen)2(mal)] Æ 2H2O, [Mn(phen)2(mal)] Æ
2H2O and [Ag2(phen)3(mal)] Æ 2H2O were synthesised
and characterised by the methods outlined by McCann
et al. [6]. All cell culture reagents and media were pur-
chased from Euroclone, UK, unless otherwise stated.
2.2. Model cell lines
A-498 (human kidney adenocarcinoma) and Hep-G2
(human hepatocellular carcinoma) cells were purchased
from the American Type Culture Collection, Manassas,
USA. Both cell types were maintained in Eagle’s mini-
mum essential medium (EMEM) with Earle’s balanced
salt solution (EBSS) containing 1.5 g/L sodium bicarbon-
ate, 2 mM L-glutamine, 0.1 mM non-essential amino
acids, 1 mM sodium pyruvate, 100 U/ml penicillin,
100 lg/ml streptomycin and 10% (v/v) foetal bovine
serum (Sigma). Both cell lines were grown at 37 C in a
humidified atmosphere with 5% CO2 and were in the
exponential phase of growth at the time of inclusion in
cytotoxicity assays.
2.3. Assessment of cytotoxicity using MTT assay
Phen, [Cu(phen)2(mal)] Æ 2H2O, [Mn(phen)2(mal)] Æ
2H2O, [Ag2(phen)3(mal)] Æ 2H2O, Cu(ClO4)2 Æ 6H2O,
Mn(ClO4)2 Æ 6H2O, AgClO4 and cisplatin were dissolved
in DMSO, diluted in culture media and used to treat
model cell lines over a drug concentration range of
0–1000 lM for a period of 96 h. The maximum percentage
of DMSO present in all wells was 0.2% (v/v). Cells were
seeded in sterile 96-well flat-bottomed plates (Sarstedt)
at a density of 5 · 104 cells cm3 and grown in 5% CO2
at 37 C. A miniaturised viability assay using 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) was carried out according to the method described
by Mosmann [15]. In metabolically active cells, MTT is
reduced by the mitochondrial enzyme succinate dehydro-
genase to form insoluble purple formazan crystals that are
subsequently solubilised, and the optical density (OD)
measured spectrophotometrically. Therefore, drug treated
cells were assayed by the addition of 20 ll of 5 mg/ml
MTT in 0.1 M phosphate buffer saline (PBS), pH 7.4.
Following incubation for 4 h at 37 C, the overlying
media was aspirated with a syringe and 100 ll of DMSOwas added to dissolve the formazan crystals. Plates were
agitated at high speed to ensure complete dissolution of
crystals and OD was measured at 550 nm using an Anthos
HT-II microtitreplate reader. Viability was expressed as a
percentage of solvent-treated control cells. Each drug con-
centration had five replicates per assay and each experi-
ment was carried out on at least three separate
occasions. The IC50 value was calculated for each drug
and used as a parameter to compare the cytotoxicity of
each test compound. Consequently, the IC50 was defined
as the drug concentration (lM) causing a 50% reduction
in cellular viability.
2.4. DNA synthesis studies
The effect of phen and each of the three phen–metal
complexes on DNA synthesis was determined using a 5-
bromo-2-deoxyuridine (BrdU) colourimetric incorpora-
tion assay [16]. One hundred microliters of A-498 and
Hep-G2 cells were seeded at a density of 5 · 104 cells/
well into 96-well plates and allowed to adhere overnight
at 37 C in a humid atmosphere with 95% air and 5%
CO2. Cells were incubated with test drug for 96 h. BrdU
was added to each well to give a final concentration of
10 lM and incubated for 4 h at 37 C. Following
removal of media, cells were permeabilised and fixed
by the addition of FixDenatTM solution (200 ll/well),
and then incubated at room temperature for 30 min,
after which the reagent was removed. Incorporated
BrdU was detected by the addition of anti-BrdU-POD
antibody conjugate (100 ll/well) (Roche), followed by
incubation at room temperature for 2 h. Plates were
washed three times with wash buffer (supplied by the
manufacturer), followed by the addition of TMB sub-
strate solution (100 ll/well) and incubation at room
temperature for 30 min, and were protected from light.
The reaction was then stopped by the addition of 1 M
H2SO4 (25 ll/well). OD of samples was measured on
a Sunrise ELISA reader at 450 nm (reference wave-
length 690 nm). Results for drug treated cells were
expressed as percentage BrdU incorporation (DNA syn-
thesis) of the solvent-treated control cells. Each drug
concentration had five replicates per assay and each
experiment was carried out on at least three separate
occasions.
2.5. DNA binding studies
pGEM-3Z plasmid DNA was purified from Escherichia
coli [strain JM 109 as previously cultured in LB broth
(Oxoid), containing 50 lg/ml ampicillin] using a Qiagen
isolation kit (Qiagen Ltd.). DNA purity and concentra-
tion was determined spectrophotometrically using A260/
A280 spectrophotometric measurements. DNA concentra-
tion was adjusted to 1 lg/ml using 10 mM Tris–HCl, pH
7.5, containing 1 mM EDTA. Drug binding assays were
Table 1
Cytotoxic potential of phen and its metal-based complexes was
determined using A-498 and Hep-G2 cells, following 96 h
continuous incubation in the range of 0–1000 lM, using MTT
viability assay
Compound A-498 IC50
(lM) ± SEM
Hep-G2 IC50
(lM) ± SEM
Phen 5.8 ± 0.31 4.1 ± 0.54
[Cu(phen)2
(mal)] Æ 2H2O
3.8 ± 0.41a 0.8 ± 0.02a
[Mn(phen)2
(mal)] Æ 2H2O
4.2 ± 0.57a 0.8 ± 0.07a
[Ag2(phen)3
(mal)] Æ 2H2O
4.0 ± 0.32a 4.7 ± 0.26
Cu(ClO4)2 Æ 6H2O 973.3 ± 26.67 >1000.00
Mn(ClO4)2 Æ 6H2O 880.0 ± 20.00 626.7 ± 27.29
AgClO4 44.4 ± 2.34 7.6 ± 0.70
Cisplatin 14.0 ± 1.00 15.0 ± 2.65
A graph of viability versus drug concentration was used to cal-
culate all IC50values (lM), n = 5.
a Value is statistically distinct from that of the parent ligand at
p < 0.05.
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simple metal salts, according to the method described by
Lorcozio and Long [17]. Briefly, DNA was incubated
for 2 h at 37 C. Doxorubicin was employed as a positive
control throughout. DNA was separated on a 1% (w/v)
agarose gel in TBE (80 mM Tris–HCl, pH 8; 40 mM boric
acid; and 2 mM EDTA), and stained with ethidium bro-
mide (5 lg/ml in TBE). Bands were visualised by irradia-
tion at 300 nm and photographed using a Pharmaciae 3D
imaging system.
2.6. Plate incorporation mutagenicity assay
A standard Ames test was carried out using phen and
three metal–phen complexes at concentration points close
to the IC50 value (0–10 lM) as determined by MTT assay
(Section 2.3). Salmonella typhimurium tester strains, TA
98 and TA102, were used to detect possible mutation by
both frame-shift and base-pair substitution, respectively.
Additionally, the mutagenic potential of phase I metabo-
lites was determined by the inclusion of an S9 fraction
isolated from rat hepatocytes, where the animal had pre-
viously been exposed to Aroclor 1254. The number of
revertant colonies was determined and related to drug
concentration [18].3. Results
All test agents were incubated with the two model cell
lines for a period of 96 h, after which cellular viability was
determined using MTT. Results obtained for phen, its
three metal–phen complexes and simple metal salts were
determined and are presented in Figs. 2 and 3. These
graphs were used to calculate the IC50 values and are pre-
sented in Table 1. Phen and the three metal–phen com-
plexes displayed a concentration-dependent cytotoxic
profile in both cell lines. Since the IC50 values for
[Cu(phen)2(mal)] Æ 2H2O, [Mn(phen)2(mal)] Æ 2H2O and
[Ag2(phen)3(mal)] Æ 2H2O were statistically slower than
that for metal-free phen in A-498 cells, it suggested that
coordinated metal ions play a major role in mediating
potency of the complex. Also, while the IC50 values for
metal-free phen and [Ag2(phen)3(mal)] Æ 2H2O on Hep-
G2 cells were not statistically different, [Cu(phen)2-
(mal)] Æ 2H2O and [Mn(phen)2(mal)] Æ 2H2O displayed a
greater effect against this cell line. This latter result
suggests that in general, Hep-G2 may be more sensitive
than A-498 cells. Significantly, phen and its metal
complexes exhibited substantially greater cytotoxicity
than cisplatin and this was found in both model cell lines.
In order to prove that the cytotoxicity observed was
due to the metal–phen complexes, rather than to simple
aquated metal ions of the type [M(H2O)x]
y+ [M = Cu(II),
Mn(II), Ag(I)], the phen-free metal salts Cu(ClO4)2 Æ
6H2O, Mn(ClO4)2 Æ 6H2O and AgClO4 were screened
against both model cell lines (Fig. 3, Table 1). The datasuggest that only AgClO4 displayed notable activity,
being more potent against Hep-G2 cells than cisplatin,
but less effective than phen and its metal complexes.
In an attempt to elucidate the events responsible for
the reduction in cellular viability, the effect on DNA syn-
thesis was determined using BrdU incorporation assays.
Results obtained suggest that phen and the metal–phen
complexes caused a dose-dependent decrease in DNA syn-
thesis, following a 96 h incubation period (Fig. 4). This
trend is consistent with viability data obtained from
MTT assays (Fig. 2).
To explore the relationship between the observed cyto-
toxic response and the possibility that DNA was a molec-
ular target, intercalation studies were carried out using
electrophoretic mobility shift assays. Additionally, the
planer structure of the phen ligand (Fig. 1) might imply
the possible involvement of intercalation in mediating
the toxic response. Treatment of pGEM-3Z plasmid
DNA with phen, the metal–phen complexes and the sim-
ple metal salts at concentrations of 1, 10 and 200 lM did
not alter the migration of any of the three forms of DNA
(super-coiled, linear, and open-circular), unlike the posi-
tive control doxorubicin (Fig. 5). This data indicates that
phen and its metal-based complexes do not intercalate
DNA and so may function by an alternative mechanism.
Additionally, in order to determine the mutagenic
potential of these compounds, the Standard Ames test
was carried out. The results presented in Fig. 6 showed
that phen, [Cu(phen)2(mal)] Æ 2H2O, and their phase I
metabolites were non-mutagenic. Similar results were
obtained for [Mn(phen)2(mal)] Æ 2H2O and [Ag2(phen)3-
(mal)] Æ 2H2O (data not shown). Finally, the results
presented here confirm that phen, and particularly the
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Fig. 2. Effects of phen and the three metal-based phen complexes on the viability of (A) A-498 (B) Hep-G2 cells. All compounds showed a
concentration-dependent decrease in viability and in both cell lines, following 96 h incubation (0–1000 lM). Results are expressed as
percentage viability of solvent-treated control cells. Bars indicate ± SEM, n = 3.
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capable of decreasing both cellular viability and DNA
synthesis, but without the involvement of intercalation
or mutation.4. Discussion
Phen and its copper complexes have previously
been shown to exert a range of biological activities,
such as anti-tumour [19], anti-Candida [20], anti-my-
cobacterial [21] and anti-microbial [22] effects. In
this study we attempted to identify the chemothera-
peutic potential of phen and the three metal–phen
complexes, [Cu(phen)2(mal)] Æ 2H2O, [Mn(phen)2-
(mal)] Æ 2H2O, and [Ag2(phen)3(mal)] Æ 2H2O, along
with characterising key aspects of their in vitro
mode of action. Additionally, the current study rep-
resents the first thorough examination of this poten-
tial application of phen and metal-based phen
complexes as novel therapeutic agents for the treat-
ment of cancer. Two human-derived epithelial cell
lines were used throughout. Initial studies were car-
ried out to determine IC50 values for phen, the three
metal–phen complexes, along with the three simplemetal salts and cisplatin. It was intended that this
approach would allow us to identify whether the
effects observed were due to the whole metal–phen
complex rather than the simple aquated metal ion,
along with comparing their relative potency to that
of cisplatin. Initial viability studies show that fol-
lowing 96 h exposure, phen and each of the metal–
phen complexes had IC50 values significantly lower
than that recorded for cisplatin. This result,
although encouraging, was not unexpected, as
Zhang and Lippard [23] had previously published
findings to suggest that a ternary copper–phen com-
plex [Cu(phen)(L-threonine)(H2O)](ClO4), when
exposed to human epithelial cell lines, displayed
IC50 values in the lM range, and cytotoxicity
greater than cisplatin. Findings from each of these
earlier studies serve to substantiate the results
obtained here. Additionally, the present study has
shown that metal-free phen and the metal–phen
complexes displayed a concentration-dependent
cytotoxic response, with Hep-G2 cells appearing to
be the most susceptible (Table 1, Fig. 2). Also, with
the exception of [Ag2(phen)3(mal)] Æ 2H2O in Hep-
G2 cells, the results suggest that the addition of a
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Fig. 3. Effects of simple transition metal salts, Cu(ClO4)2 Æ 6H2O, Mn(ClO4)2 Æ 6H2O and AgClO4 on the viability of (A) A-498 and (B)
Hep-G2 cells. All salts promoted a decrease in viability following 96 h incubation (0–1000 lM). However, AgClO4 appeared to be the most
potent, and in both cell lines. Results are expressed as percentage viability of solvent-treated control cells. Bars indicate ± SEM, n = 3.
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icity. The possibility that observed cytotoxicity for
the metal–phen complexes may be due to the
phen-free simple solvated Cu(II), Mn(II) and
Ag(I) ions was also tested. The results obtained
clearly indicated that although AgClO4 was the
most potent simple salt (Fig. 3) it was still less cyto-
toxic than phen and the metal–phen complexes.
Similar results have previously been published
where AgClO4, at concentrations in the range of
4–82 lM were shown to kill human dermal fibro-
blasts [24]. So, while AgClO4 processes cytotoxic
properties, it would appear that it is less cytotoxic
than either phen or the three metal–phen complexes
studied here.
In an attempt to explore the molecular mecha-
nism(s) underlying the observed cytotoxic response,
BrdU incorporation studies were conducted. DNA
synthesis is known to be critical to cell division.
Therefore, any chemotherapeutic agent that can sig-
nificantly reduce DNA synthesis is likely to be of
particular interest in controlling cancer cell division.
The data presented here suggest that phen and its
metal-based complexes are capable of inhibitingDNA synthesis in both cell lines and in a concentra-
tion-dependent manner. However, again Hep-G2
cells appeared to be most sensitive. Furthermore,
the presence of a metal ion coordinated to the phen
ligand did not serve to enhance the observed
inhibition. This suggests that the phen ligand itself
may play a significant role in mediating DNA
inhibition. However, the current data did not
explain the relationship between exposure to phen-
based compounds and decreased DNA synthesis
and ultimately cell death, suggesting the necessity
for additional mechanistic studies.
A number of researchers have focused consider-
able attention on determining whether DNA could
be a primary target for phen-containing com-
pounds. Studies have shown that bis(1,10-phenan-
throline)-copper(II) can efficiently cleave DNA in
the presence of thiol and hydrogen peroxide [25–
27]. These researchers have suggested that DNA
strand scission may occur through non-covalently
binding to the minor groove of DNA and reacting
with hydrogen peroxide. In 2004, Zhang et al. [28]
showed that a ternary copper(II) complex of phe-
nanthroline and L-threonine were capable of both
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Fig. 4. Effects of phen and three metal-based phen complexes on
DNA synthesis in (A) A-498 and (B) Hep-G2 cells, following
continuous exposure for 96 h. All compounds produced a dose-
dependent decrease in DNA synthesis. Bars indicate ± SEM,
n = 3.
230 C. Deegan et al. / Cancer Letters 247 (2007) 224–233binding to DNA by intercalation and were also able
to cleave DNA in the presence of ascorbate. However,
they suggest that the introduction of the L-threonine
rather than the phen ligand was primarilyLane no: 1  2 3  4    5 
Fig. 5. Electrophoretic mobility shift assays were used to determine the
pGEM-3Z supercoiled plasmid DNA for 2 h at 37 C, analysed by aga
indicate that neither compound inhibited migration of super coiled (SC)
not intercalate DNA. Lane 1 negative control (pGEM-3Z DNA only); l
lanes 3–5 phen (pGEM-3Z DNA and Phen at 1, 10, and 200 lM);
[Cu(phen)2(mal)] Æ 2H2O at 1, 10, and 200 lM). Similar results were obresponsible for these effects. Additionally, Mehes-
wari and Palaniandavar [29] used a number of
tetrammine ruthenium(II) complexes of modified
phen to show that the planarity of the modified
phen ligand plays an important role in dictating
DNA binding affinity. More recently, Heffeter
et al. [30] found that a lanthanum derivative of
phen, [tris(1,10-phen)lanthanum(III) trithiocyanate,
was a potent anticancer agent and this suggest
that DNA was not likely to be the primary target.
This theory was based on a lack of evidence for
any significant interaction with or damage to
DNA. In the current study we attempted to explore
the possibility that phen and the three metal–phen
complexes could intercalate DNA. The model used
to demonstrate intercalation was gel mobility shift
assays originally advanced by Waring [31]. This
model proposes that intercalating ligands must pos-
sess a planar aromatic ring structure capable of
hydrophobic interactions with DNA base pairs
and that on binding of the ligand, the double helix
should become extended and locally uncoiled. Local
unwinding of the double helix by an intercalating
species results in an increase in the size of the
DNA molecule. The super-coiled form of plasmid
DNA migrates further than linear or open circular
forms and can be detected by electrophoretic
migration assays [32]. DNA was exposed to phen
and the metal–phen complexes over a range of
concentrations above and below their IC50 values
(Table 1). The results presented in Fig. 5 clearly
indicate that none of these agents were capable of
retarding the electrophoretic mobility of supercoiled 
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Fig. 6. Standard Ames tests were used to determine the mutagenic potential of all test compounds using Salmonella typhimurium tester
strains, TA 98 and TA102, both in the presence and absence of S9 fraction isolated from rat hepatocytes, where the animal had previously
been exposed to Aroclor 1254. Results are presented for phen and [Cu(phen)2(mal)] Æ 2H2O (0–10 lM/plate) and indicate that neither of
these compounds are mutagenic as they do not cause a dose-dependent increase in the number of revertant colonies. Similar data were
obtained for [Mn(phen)2(mal)] Æ 2H2O and [Ag2(phen)3(mal)] Æ 2H2O (data not shown). Bars indicate ± SEM, n = 3.
C. Deegan et al. / Cancer Letters 247 (2007) 224–233 231pGEM-3Z DNA, suggesting that they did not
intercalate DNA. These findings imply that the inhi-
bition observed may operate through an alternative
mechanism. In addition, they also serve to confirm
the findings of Heffeter et al. [30].
Additionally, it was decided to determine the
mutagenic potential of each of the compounds usingthe standard Ames test. Further assays were also car-
ried out in the presence of an S9 fraction derived from
rat hepatocytes, thereby allowing the mutagenic
potential of phase I metabolites to be determined.
The results presented in Fig. 6 show that none of
the compounds caused a significant increase in the
number of revertant colonies, either by base-pair
232 C. Deegan et al. / Cancer Letters 247 (2007) 224–233substitution or by frame-shift, suggesting that they
and their metabolites were non-mutagenic. These
findings clearly indicate that if phen and metal–phen
complexes were to be employed therapeutically, their
potential is not likely to be limited by mutagenicity.
In conclusion, the above findings suggest that
phen, [Mn(phen)2(mal)] Æ 2H2O, and particularly
[Cu(phen)2(mal)] Æ 2H2O and [Ag2(phen)3(mal)] Æ
2H2O are capable of decreasing cancer cell viability
through an inhibition of DNA synthesis. Studies
are currently underway in our laboratory to investi-
gate more fully the mechanisms by which phen and
the three metal–phen complexes control cancer cell
viability. It is intended that the results from these
studies will allow identification of key molecular tar-
gets, and in doing so will assist in elucidating their
mechanisms of action, along with facilitating the
development of highly effective anti- cancer therapies.Acknowledgements
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